Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;6(4):337-353.
doi: 10.1007/s40674-020-00160-z. Epub 2020 Sep 1.

Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment

Sicong Huang  1 , Vanessa L Kronzer  2 , Paul F Dellaripa  1 , Kevin D Deane  3 , Marcy B Bolster  4 , Vivek Nagaraja  5 , Dinesh Khanna  5 , Tracy J Doyle  6 , Jeffrey A Sparks  1
Affiliations

Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment

Sicong Huang et al. Curr Treatm Opt Rheumatol. 2020 Dec.

Abstract

Purpose of review: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the most serious extra-articular RA manifestations. RA-ILD is associated with worse physical function, lower quality of life, and increased mortality. RA-ILD is comprised of heterogeneous subtypes characterized by inflammation and fibrosis. Diagnosis can be difficult since the presentation of RA-ILD is characterized by non-specific symptoms and imaging findings. Management of RA-ILD is also challenging due to difficulty in precisely measuring pulmonary disease activity and response to treatment in patients who may also have articular inflammation. We provide a current overview of RA-ILD focusing on prevalence, risk factors, and treatment.

Recent findings: Research interest in RA-ILD has increased in recent years. Some studies suggest that RA-ILD prevalence may be increasing; this may be due to underlying biologic drivers or increases in imaging and recognition. Novel RA-ILD risk factors include the MUC5B promotor variant, articular disease activity, autoantibodies, and biomarkers of damaged pulmonary parenchyma. Treatment should focus on controlling RA disease activity, which emerging data suggest may reduce RA-ILD risk. Immunomodulatory and antifibrotic drugs may also treat RA-ILD.

Summary: RA-ILD is an underrecognized and serious manifestation of RA, but important progress is being made in identifying risk factors and treatment.

Keywords: DMARDs; interstitial lung disease; pulmonary; rheumatoid arthritis; treatment.

PubMed Disclaimer

References

    1. Yoshida K, Lin TC, Wei M, Malspeis S, Chu SH, Camargo CA, et al. The roles of post-diagnosis accumulation of morbidities and lifestyle changes on excess total and cause-specific mortality risk in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019. doi: 10.1002/acr.24120. - DOI - PMC - PubMed
    2. *Large study with lengthy follow-up demonstrating accumulation of morbidities and excess respiratory mortality for patients with seropositive RA.
    1. Sparks JA, Chang SC, Liao KP, Lu B, Fine AR, Solomon DH, et al. Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses’ Health Study. Arthritis Care Res (Hoboken). 2016;68(6):753–62. doi: 10.1002/acr.22752. - DOI - PMC - PubMed
    1. England BR, Sayles H, Michaud K, Caplan L, Davis LA, Cannon GW, et al. Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68(1):36–45. doi: 10.1002/acr.22642. - DOI - PubMed
    1. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–91. doi: 10.1002/art.27405. - DOI - PMC - PubMed
    1. Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, Lokke A, Bendstrup E, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76(10):1700–6. doi: 10.1136/annrheumdis-2017-211138. - DOI - PubMed
    2. **Large nationwide study investigating incidence and prevalance of RA-ILD in relation to RA onset.

LinkOut - more resources